Literature DB >> 12818284

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

Takeshi Saito1, Takayoshi Ito, Hiroaki Ishiko, Mari Yonaha, Kenichi Morikawa, Akio Miyokawa, Keiji Mitamura.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) E2 protein was recently reported to have a double-stranded RNA-activated protein kinase-eukaryotic initiation factor 2alpha (PKR-eIF2alpha) phosphorylation homology domain (PePHD); PKR is induced by interferon (IFN). PePHD interacts with PKR and inactivates it. PePHD could be a predictor for IFN response, like the interferon sensitivity determination region (ISDR) of HCV NS5A. Several groups reported that PePHD is conserved, and mutations in this region do not correlate with IFN response. In this study, we further investigated the amino acid variation of PePHD among four major genotypes and its correlation with IFN response.
METHODS: We enrolled 74 patients for this study and determined PePHD sequence of HCV derived from sera of patients infected with HCV genotype 1a (1 patient; nonresponder [NR]), 1b (36 patients; 4 complete responders [CR], 32 NR), 2a (29 patients; 17 CR, 12 NR), and 2b (8 patients; 3 CR, 5 NR). We also analyzed mutations in ISDR of HCV genotype 1b in 31 patients.
RESULTS: PePHD had several variations among four genotypes investigated. In patients infected with HCV genotype 1b, PePHD sequence was well conserved and seemed to have no correlation with IFN response. Mutations in ISDR were correlated with IFN response. In patients with HCV genotypes 2a and 2b, PePHD had multiple variations, and one particular motif, "RGQQ-" at the N-terminus, showed a close correlation with IFN resistance. All eight patients with HCV containing this motif were IFN nonresponders.
CONCLUSIONS: IFN resistance of HCV correlates with its "RGQQ-" motif at the N-terminus of PePHD in HCV genotype 2a and 2b. PePHD of HCV could be a predictor of IFN resistance in patients infected with HCV genotype 2a and 2b.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818284     DOI: 10.1111/j.1572-0241.2003.07469.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

Review 1.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy.

Authors:  Makoto Kadokura; Shinya Maekawa; Ryota Sueki; Mika Miura; Kazuki Komase; Hiroko Shindo; Fumitake Amemiya; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Mina Nakagawa; Naoya Sakamoto; Mamoru Watanabe; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-03-20       Impact factor: 6.047

3.  Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.

Authors:  Koji Ukai; Masatoshi Ishigami; Kentaro Yoshioka; Naoto Kawabe; Yoshiaki Katano; Kazuhiko Hayashi; Takashi Honda; Motoyoshi Yano; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Authors:  Catherine Gaudy; Marie Lambelé; Alain Moreau; Pascal Veillon; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 5.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

Review 6.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

7.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

8.  Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Authors:  John E Tavis; Maureen J Donlin; Rajeev Aurora; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Genome Med       Date:  2011-02-08       Impact factor: 11.117

9.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

Review 10.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.